Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone-Sensitive Prostate Cancer.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2025-05-06 eCollection Date: 2025-01-01 DOI:10.1177/11795549251335166

Mona Ali Hassan, Shobana Anpalakhan, Marina Campione, Akash Maniam, Naoko Atsumi, Shyamika Acharige, Utku Lokman, Hajra Iqbal, Tomasz Olejnik, Maja Uherek, Daniel Wilby, Richard Robinson, Joanna Buckley, Joanna Gale, Giuseppe Luigi Banna

{"title":"Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Mona Ali Hassan, Shobana Anpalakhan, Marina Campione, Akash Maniam, Naoko Atsumi, Shyamika Acharige, Utku Lokman, Hajra Iqbal, Tomasz Olejnik, Maja Uherek, Daniel Wilby, Richard Robinson, Joanna Buckley, Joanna Gale, Giuseppe Luigi Banna","doi":"10.1177/11795549251335166","DOIUrl":null,"url":null,"abstract":"Background: Computed tomography with bone scans (CT-B) has been widely used for staging metastatic hormone-sensitive prostate cancer (mHSPC), but whole-body magnetic resonance imaging (WB-MRI) is increasingly adopted. This study compares WB-MRI and CT-B in detecting metastatic sites, disease classification (CHAARTED and LATITUDE), and treatment outcomes in mHSPC.Methods: This retrospective study included patients with mHSPC diagnosed between February 2017 and August 2023 at 2 UK NHS hospitals. Patients underwent baseline staging with either WB-MRI or CT-B. Data on demographics, disease extent, and treatment were analysed. Patients were stratified using CHAARTED and LATITUDE criteria. Survival outcomes were assessed using Kaplan-Meier and Cox regression analyses.Results: Among 203 patients (120 WB-MRI, 83 CT-B), WB-MRI identified higher rates of bone-only disease (47% vs 22%, P < .001), high-volume (49% vs 22%, P < .001), high-risk (47% vs 18%, P < .001), and de novo metastatic disease (91% vs 65%, P < .001), but lower lymph node-only metastases (10% vs 26%, P = .003) and prior radical treatment (surgery: 2% vs 13%, P < .001; radiotherapy: 7% vs 25%, P < .001). CHAARTED (HR 4.922, 95% CI: 1.937-12.507, P < .0001) and LATITUDE (HR 4.807, 95% CI: 1.674-13.809, P = .003) classifications independently predicted overall survival, with significant volume/risk differences only observed in WB-MRI (P < .001 and P = .001, respectively).Conclusions: Whole-body magnetic resonance imaging appears to enhance staging accuracy and risk stratification in mHSPC, potentially influencing treatment decisions. While limited by retrospective design, these findings suggest that WB-MRI may optimise management in mHSPC, warranting further prospective validation.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251335166"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056321/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549251335166","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Computed tomography with bone scans (CT-B) has been widely used for staging metastatic hormone-sensitive prostate cancer (mHSPC), but whole-body magnetic resonance imaging (WB-MRI) is increasingly adopted. This study compares WB-MRI and CT-B in detecting metastatic sites, disease classification (CHAARTED and LATITUDE), and treatment outcomes in mHSPC.

Methods: This retrospective study included patients with mHSPC diagnosed between February 2017 and August 2023 at 2 UK NHS hospitals. Patients underwent baseline staging with either WB-MRI or CT-B. Data on demographics, disease extent, and treatment were analysed. Patients were stratified using CHAARTED and LATITUDE criteria. Survival outcomes were assessed using Kaplan-Meier and Cox regression analyses.

Results: Among 203 patients (120 WB-MRI, 83 CT-B), WB-MRI identified higher rates of bone-only disease (47% vs 22%, P < .001), high-volume (49% vs 22%, P < .001), high-risk (47% vs 18%, P < .001), and de novo metastatic disease (91% vs 65%, P < .001), but lower lymph node-only metastases (10% vs 26%, P = .003) and prior radical treatment (surgery: 2% vs 13%, P < .001; radiotherapy: 7% vs 25%, P < .001). CHAARTED (HR 4.922, 95% CI: 1.937-12.507, P < .0001) and LATITUDE (HR 4.807, 95% CI: 1.674-13.809, P = .003) classifications independently predicted overall survival, with significant volume/risk differences only observed in WB-MRI (P < .001 and P = .001, respectively).

Conclusions: Whole-body magnetic resonance imaging appears to enhance staging accuracy and risk stratification in mHSPC, potentially influencing treatment decisions. While limited by retrospective design, these findings suggest that WB-MRI may optimise management in mHSPC, warranting further prospective validation.

Abstract Image

查看原文本刊更多论文

磁共振或计算机断层扫描和骨扫描对转移性激素敏感前列腺癌的分期。

背景：骨扫描计算机断层扫描（CT-B）已广泛用于转移性激素敏感性前列腺癌（mHSPC）的分期，但全身磁共振成像（WB-MRI）越来越多地被采用。本研究比较了WB-MRI和CT-B在检测转移部位、疾病分类（charted和LATITUDE）和mHSPC治疗结果方面的差异。方法：本回顾性研究纳入了2017年2月至2023年8月在2家英国NHS医院诊断的mHSPC患者。患者通过WB-MRI或CT-B进行基线分期。分析了人口统计学、疾病程度和治疗方面的数据。采用charted和LATITUDE标准对患者进行分层。采用Kaplan-Meier和Cox回归分析评估生存结果。结果：203例患者（120例WB-MRI， 83例CT-B）中，WB-MRI鉴定出更高的仅骨疾病发生率（47% vs 22%, P P P P = 0.003）和既往根治性治疗（手术：2% vs 13%， P P P P = 0.003）分类独立预测总生存率，仅在WB-MRI中观察到显著的体积/风险差异（P P = 0.003）。001年,分别)。结论：全身磁共振成像似乎可以提高mHSPC的分期准确性和风险分层，可能影响治疗决策。虽然受到回顾性设计的限制，但这些发现表明，WB-MRI可以优化mHSPC的管理，需要进一步的前瞻性验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.